Endo debuts bivalirudin injection in ready-to-use vials

Endo’s Par Sterile Products business has begun shipping bivalirudin injection in a ready-to-use 250 mg/50 ml single-use vial. It is the only ready-to-use liquid format of bivalirudin on the market in the United States, the company noted. 

"Hospital practitioners work hard to provide quality patient care while also meeting operational challenges," said Scott Sims, senior vice president and general manager of injectable solutions and generics at Endo. "With ready-to-use products like bivalirudin, we're helping to deliver solutions that reduce complexity for healthcare providers—so they can focus on patient care."

In May 2023, Endo executed agreements with MAIA Pharmaceuticals and Gland Pharma, India to commercialize ready-to-use bivalirudin in the United States. The product, manufactured by Gland Pharma, is an anticoagulant (thrombin inhibitor) that helps prevent the formation of blood clots in people with severe chest pain or other conditions who are undergoing an angioplasty procedure.

[Read more: Endo to distribute bivalirudin injection in ready-to-use vials]

Ready-to-use products streamline operations for hospitals by eliminating the need to prepare or transfer the product before patient administration. This may reduce waste and costs, optimize convenience and workflow and reduce the chance for preparation error—all of which support quality patient care, Endo said.

[Read more: Par launches generic Pylera]